ORIC Pharma Files 8-K on Operations & Financial Condition

Ticker: ORIC · Form: 8-K · Filed: Jan 9, 2024 · CIK: 1796280

Oric Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyOric Pharmaceuticals, Inc. (ORIC)
Form Type8-K
Filed DateJan 9, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: financial-condition, operations, regulation-fd, corporate-filing

TL;DR

**ORIC just dropped an 8-K with fresh financial and operational deets.**

AI Summary

Oric Pharmaceuticals, Inc. filed an 8-K on January 9, 2024, to report on its results of operations and financial condition, as well as to make a Regulation FD disclosure. This filing, under SEC File Number 001-39269, indicates that the company is providing updated financial information. For investors, this matters because it provides a snapshot of the company's recent financial health and operational performance, which can influence stock valuation and future investment decisions.

Why It Matters

This filing provides investors with current financial and operational updates, which are crucial for assessing the company's performance and making informed investment decisions.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial and operational information, not indicating any immediate high-risk events.

Analyst Insight

A smart investor would review the detailed financial and operational information that Oric Pharmaceuticals, Inc. will provide in conjunction with this 8-K to understand the company's current performance and future outlook before making any investment decisions.

Key Numbers

  • 001-39269 — SEC File Number (identifies the company's registration with the SEC)
  • 2024-01-09 — Date of Report (indicates the earliest event reported in the filing)
  • 56 — Public Document Count (number of documents associated with this accession)

Key Players & Entities

  • Oric Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
  • 001-39269 (dollar_amount) — SEC File Number
  • January 9, 2024 (date) — Date of earliest event reported and filing date
  • Nasdaq Global Select Market (company) — exchange where ORIC common stock is registered
  • ORIC (company) — trading symbol for Oric Pharmaceuticals, Inc.

FAQ

What is the primary purpose of this 8-K filing by Oric Pharmaceuticals, Inc.?

The primary purpose of this 8-K filing, dated January 9, 2024, is to report on the company's results of operations and financial condition, and to make a Regulation FD Disclosure, as indicated in the 'ITEM INFORMATION' section.

On what date was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on January 9, 2024, as stated under 'Date of Report (Date of earliest event reported) January 9, 2024'.

What is the trading symbol and the exchange where Oric Pharmaceuticals, Inc.'s common stock is registered?

Oric Pharmaceuticals, Inc.'s common stock, with a par value of $0.0001 per share, trades under the symbol 'ORIC' on The Nasdaq Global Select Market, as listed under 'Securities registered pursuant to Section 12(b) of the Act'.

What is the business address and phone number of Oric Pharmaceuticals, Inc. as listed in the filing?

The business address of Oric Pharmaceuticals, Inc. is 240 E. Grand Ave, 2nd Floor, South San Francisco, CA 94080, and its telephone number is (650) 388-5600, according to the 'BUSINESS ADDRESS' section.

What is the SEC File Number for Oric Pharmaceuticals, Inc.?

The SEC File Number for Oric Pharmaceuticals, Inc. is 001-39269, as specified in the 'FILER' and 'FORM 8-K' sections of the filing.

Filing Stats: 540 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2024-01-09 09:00:42

Key Financial Figures

  • $0.0001 — ich registered Common stock, par value $0.0001 per share ORIC The Nasdaq Global Se

Filing Documents

02

Item 2.02 Results of Operations and Financial Condition. The information set forth in Item 7.01 is hereby incorporated by reference into this Item 2.02.

01

Item 7.01 Regulation FD Disclosure. ORIC Pharmaceuticals, Inc. (the "Company") intends to present an updated corporate presentation (the "Corporate Presentation") at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. A copy of the Corporate Presentation is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. All of the information furnished in this Item 7.01 and Items 2.02 and 9.01 (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Corporate Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ORIC PHARMACEUTICALS, INC. Date: January 9, 2024 By: /s/ Christian Kuhlen Christian Kuhlen, M.D., J.D. General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.